Cargando…
Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets
Both oncogenic and tumor suppressor functions have been described for junction plakoglobin (JUP), also known as γ‐catenin. To clarify the role of JUP in prostate cancer, JUP protein expression was immunohistochemically detected in a tissue microarray containing 11 267 individual prostatectomy specim...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253102/ https://www.ncbi.nlm.nih.gov/pubmed/33533127 http://dx.doi.org/10.1002/1878-0261.12922 |
_version_ | 1783717441269923840 |
---|---|
author | Spethmann, Tanja Böckelmann, Lukas Clemens Labitzky, Vera Ahlers, Ann‐Kristin Schröder‐Schwarz, Jennifer Bonk, Sarah Simon, Ronald Sauter, Guido Huland, Hartwig Kypta, Robert Schumacher, Udo Lange, Tobias |
author_facet | Spethmann, Tanja Böckelmann, Lukas Clemens Labitzky, Vera Ahlers, Ann‐Kristin Schröder‐Schwarz, Jennifer Bonk, Sarah Simon, Ronald Sauter, Guido Huland, Hartwig Kypta, Robert Schumacher, Udo Lange, Tobias |
author_sort | Spethmann, Tanja |
collection | PubMed |
description | Both oncogenic and tumor suppressor functions have been described for junction plakoglobin (JUP), also known as γ‐catenin. To clarify the role of JUP in prostate cancer, JUP protein expression was immunohistochemically detected in a tissue microarray containing 11 267 individual prostatectomy specimens. Considering all patients, high JUP expression was associated with adverse tumor stage (P = 0.0002), high Gleason grade (P < 0.0001), and lymph node metastases (P = 0.011). These associations were driven mainly by the subset without TMPRSS2:ERG fusion, in which high JUP expression was an independent predictor of poor prognosis (multivariate analyses, P = 0.0054) and early biochemical recurrence (P = 0.0003). High JUP expression was further linked to strong androgen receptor expression (P < 0.0001), high cell proliferation, and PTEN and FOXP1 deletion (P < 0.0001). In the ERG‐negative subset, high JUP expression was additionally linked to MAP3K7 (P = 0.0007) and CHD1 deletion (P = 0.0021). Contrasting the overall prognostic effect of JUP, low JUP expression indicated poor prognosis in the fraction of CHD1‐deleted patients (P = 0.039). In this subset, the association of high JUP and high cell proliferation was specifically absent. In conclusion, the controversial biological roles of JUP are reflected by antagonistic prognostic effects in distinct prostate cancer patient subsets. |
format | Online Article Text |
id | pubmed-8253102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82531022021-07-13 Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets Spethmann, Tanja Böckelmann, Lukas Clemens Labitzky, Vera Ahlers, Ann‐Kristin Schröder‐Schwarz, Jennifer Bonk, Sarah Simon, Ronald Sauter, Guido Huland, Hartwig Kypta, Robert Schumacher, Udo Lange, Tobias Mol Oncol Research Articles Both oncogenic and tumor suppressor functions have been described for junction plakoglobin (JUP), also known as γ‐catenin. To clarify the role of JUP in prostate cancer, JUP protein expression was immunohistochemically detected in a tissue microarray containing 11 267 individual prostatectomy specimens. Considering all patients, high JUP expression was associated with adverse tumor stage (P = 0.0002), high Gleason grade (P < 0.0001), and lymph node metastases (P = 0.011). These associations were driven mainly by the subset without TMPRSS2:ERG fusion, in which high JUP expression was an independent predictor of poor prognosis (multivariate analyses, P = 0.0054) and early biochemical recurrence (P = 0.0003). High JUP expression was further linked to strong androgen receptor expression (P < 0.0001), high cell proliferation, and PTEN and FOXP1 deletion (P < 0.0001). In the ERG‐negative subset, high JUP expression was additionally linked to MAP3K7 (P = 0.0007) and CHD1 deletion (P = 0.0021). Contrasting the overall prognostic effect of JUP, low JUP expression indicated poor prognosis in the fraction of CHD1‐deleted patients (P = 0.039). In this subset, the association of high JUP and high cell proliferation was specifically absent. In conclusion, the controversial biological roles of JUP are reflected by antagonistic prognostic effects in distinct prostate cancer patient subsets. John Wiley and Sons Inc. 2021-02-17 2021-07 /pmc/articles/PMC8253102/ /pubmed/33533127 http://dx.doi.org/10.1002/1878-0261.12922 Text en © 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Spethmann, Tanja Böckelmann, Lukas Clemens Labitzky, Vera Ahlers, Ann‐Kristin Schröder‐Schwarz, Jennifer Bonk, Sarah Simon, Ronald Sauter, Guido Huland, Hartwig Kypta, Robert Schumacher, Udo Lange, Tobias Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets |
title | Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets |
title_full | Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets |
title_fullStr | Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets |
title_full_unstemmed | Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets |
title_short | Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets |
title_sort | opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253102/ https://www.ncbi.nlm.nih.gov/pubmed/33533127 http://dx.doi.org/10.1002/1878-0261.12922 |
work_keys_str_mv | AT spethmanntanja opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets AT bockelmannlukasclemens opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets AT labitzkyvera opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets AT ahlersannkristin opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets AT schroderschwarzjennifer opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets AT bonksarah opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets AT simonronald opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets AT sauterguido opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets AT hulandhartwig opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets AT kyptarobert opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets AT schumacherudo opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets AT langetobias opposingprognosticrelevanceofjunctionplakoglobinindistinctprostatecancerpatientsubsets |